Immatics NV is a biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients... Show more
IMTX moved above its 50-day moving average on April 23, 2025 date and that indicates a change from a downward trend to an upward trend. In of 52 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are .
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where IMTX's RSI Oscillator exited the oversold zone, of 32 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Momentum Indicator moved above the 0 level on April 17, 2025. You may want to consider a long position or call options on IMTX as a result. In of 86 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for IMTX just turned positive on April 14, 2025. Looking at past instances where IMTX's MACD turned positive, the stock continued to rise in of 49 cases over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where IMTX advanced for three days, in of 281 cases, the price rose further within the following month. The odds of a continued upward trend are .
IMTX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 6 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IMTX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.844) is normal, around the industry mean (14.237). P/E Ratio (28.505) is within average values for comparable stocks, (63.881). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.827). Dividend Yield (0.000) settles around the average of (0.024) among similar stocks. P/S Ratio (2.735) is also within normal values, averaging (255.011).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. IMTX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IMTX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
a clinical stage biopharmaceutical company, which engages in the research and development of T cell receptor-based immunotherapies for the treatment of cancer
Industry Biotechnology
A.I.dvisor indicates that over the last year, IMTX has been loosely correlated with RCKT. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if IMTX jumps, then RCKT could also see price increases.
Ticker / NAME | Correlation To IMTX | 1D Price Change % | ||
---|---|---|---|---|
IMTX | 100% | +3.55% | ||
RCKT - IMTX | 44% Loosely correlated | +4.06% | ||
ROIV - IMTX | 42% Loosely correlated | +2.42% | ||
ACLX - IMTX | 42% Loosely correlated | +0.53% | ||
DNTH - IMTX | 42% Loosely correlated | -1.53% | ||
CGON - IMTX | 42% Loosely correlated | +3.81% | ||
More |